Latest Funding News

Optiscan Imaging Limited reported a 17.6% revenue decline and a 4.1% increase in net loss for FY25, driven by lower orders and higher R&D spending. The company unveiled two new medical imaging devices as it ramps up commercial efforts.

Linius Technologies reported a $5.31 million loss for FY25 as it shifts towards a sales-driven SaaS model, with new leadership and cost-cutting measures aiming to reshape its future.

Qualitas Real Estate Income Fund (QRI) has declared a distribution for August 2025, delivering an annualised yield of 6.32% based on its net tangible assets. The fund continues to focus on mortgage-backed real estate loans across Australia, aiming to provide steady income and capital preservation.

Adisyn Ltd reported a sharp increase in losses for FY25, driven by a 40% revenue drop and a costly acquisition, while securing significant new equity funding.

Energy World Corporation Ltd reports a remarkable turnaround to a $346 million profit for FY25, driven by a $390 million gain from debt restructuring and the sale of a key Indonesian asset. The company faces funding challenges as it advances LNG and power projects in Southeast Asia.

Elixinol Wellness Limited reported a 12.8% revenue increase in the first half of 2025, driven by strategic acquisitions and a growing e-commerce presence, while targeting profitability by the end of the year.

Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.

Pengana Private Equity Trust reported a robust FY25 with a 7.6% NAV increase and a strong net profit of $50 million, underpinned by a diversified global private equity portfolio and a strategic buyback program.

Vmoto Limited reported a 10.8% revenue decline to $20.8 million in H1 2025 but reduced its net loss slightly to $3 million, buoyed by resilient international sales and a strategic partnership with Uber to electrify delivery fleets across Europe.

Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

DigitalX Limited posted a larger loss for FY25 despite an 18% revenue increase, driven by digital asset appreciation and a bold Bitcoin accumulation strategy.